중추신경계(CNS) 치료제 시장 : 규모, 점유율, 성장 분석, 질환별, 약제 클래스별, 유통 경로별, 지역별, 업계 예측(2026-2033년)

CNS (Central Nervous System) Therapeutics Market size was valued at USD 144.96 Billion in 2024 and is poised to grow from USD 154.09 Billion in 2025 to USD 251.22 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The Central Nervous System (CNS) Therapeutics market represents a vital segment of the healthcare and pharmaceutical landscape, offering a myriad of treatments for neurological and psychiatric disorders. As the complexities of the CNS are increasingly understood, the sector benefits from continuous innovation driven by heightened awareness of mental health challenges and a growing elderly population. Collaborative efforts between pharmaceutical companies and research organizations are propelling advancements in therapeutic methods. While the market showcases potential for significantly enhancing the quality of life for affected individuals, it also encounters hurdles such as regulatory approval processes, pricing dynamics, and competitive pressures. Stakeholders must strategically navigate these challenges to capitalize on the opportunities presented within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

CNS (Central Nervous System) Therapeutics Market Segments Analysis

Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the CNS (Central Nervous System) Therapeutics Market

The increasing aging population globally contributes to a notable rise in the incidence of neurological disorders, such as Alzheimer's and Parkinson's disease. This demographic transition significantly enhances the need for therapeutic solutions targeting the central nervous system, as the elderly are more vulnerable to these ailments. Consequently, the growing prevalence of these disorders drives the demand for advanced CNS therapies and innovative treatments, highlighting the urgency for effective medical interventions tailored to meet the needs of this expanding patient population. The focus on addressing neurological health is paramount, as it aligns with the broader goal of improving quality of life among aging individuals.

Restraints in the CNS (Central Nervous System) Therapeutics Market

The CNS Therapeutics market faces significant challenges due to the lengthy process of developing drugs for neurological and psychiatric conditions. The necessity for comprehensive clinical trials and the strict evaluations by regulatory bodies often result in delays and increased financial burdens for companies. These obstacles can stifle innovation, making it more difficult to introduce new therapies promptly. Consequently, patient access to effective treatments may be adversely affected, as the complexities of regulatory compliance slow down the development and approval of potentially life-changing therapeutics in the Central Nervous System sector.

Market Trends of the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) therapeutics market is increasingly leaning towards personalized medicine, driven by advancements in genetics and neuroimaging technologies that enhance the understanding of individual variations in CNS disorders. This trend focuses on customizing treatment strategies based on a patient's specific genetic makeup, neurobiological characteristics, and therapeutic responses, promoting more precise and effective interventions. As a result, personalized approaches are expected to transform the treatment paradigm for prevalent conditions such as Alzheimer's disease, depression, and schizophrenia, ultimately improving patient outcomes and driving growth within the CNS therapeutics sector. This evolution can lead to better efficacy and reduced side effects, shaping a more patient-centered approach in neurology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
• Parkinson's Disease
  • Multiple Sclerosis
  • Huntington's Disease
• Amytrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global CNS (Central Nervous System) Therapeutics Market Size & CAGR (2026-2033)

• North America (Disease, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neumora Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunic Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Muna Therapeutics (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NRG Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations